pubrio
WuXi Biologics/药明生物 logo

WuXi Biologics/药明生物

Public
wuxibiologics.com
제약2,900+ employeesFounded 2010🇨🇳 중국

Our Vision: "Every drug can be made and every disease can be treated" by building an open-access platform with the most comprehensive capabilities and technologies in the global biologics industry. Our Mission: To accelerate and transform the discovery, development and manufacturing of biologics through a comprehensive open-access platform, enabling our global healthcare partners and benefiting patients worldwide. Our Company: WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. The company's history and achievements demonstrate its commitment to providing a truly ONE-stop service offering and strong value proposition to its global clients. With total estimated capacity for biopharmaceutical production planned in the U.S., China, Ireland, Germany, and Singapore exceeding 430,000 liters after 2024, WuXi Biologics will provide its biomanufacturing partners with a robust and premier-quality global supply chain network.

설립
2010
직원
2,900+
산업
제약
회사 유형
Public Company
주식
hkse: 2269.HK
본사
🇨🇳108 Meiliang Road, Mashan, Binhu District, Wuxi, Jiangsu, China, 214092, Wuxi, Jiangsu 214092, Cn (+9)
전문 분야
제약생명 공학의료

확장 인텔리전스

NEW · Pubrio 단독

WuXi Biologics/药明生物의 시장 확장을 추적하고 있습니다

글로벌 확장

실시간
단계
탐색 중투자 중진입 중운영 중

활동 펄스

신규 사업 거점 활동 — 새 시그널 9건이 방금 나타났습니다.

최근 90일
채용
5-33%
채용
마케팅 및 PR
0
활동 없음
제품 및 기술
1종료
제품 출시
+2개 카테고리 더잠김
5개 중 3개 표시
알아두면 좋은 정보

WuXi Biologics/药明生物 관련 자주 묻는 질문

WuXi Biologics/药明生物의 사업, 시장, 성장 시그널에 대한 빠른 답변입니다.

Our Vision: "Every drug can be made and every disease can be treated" by building an open-access platform with the most comprehensive capabilities and technologies in the global biologics industry. Our Mission: To accelerate and transform the discovery, development and manufacturing of biologics through a comprehensive open-access platform, enabling our global healthcare partners and benefiting patients worldwide. Our Company: WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. The company's history and achievements demonstrate its commitment to providing a truly ONE-stop service offering and strong value proposition to its global clients. With total estimated capacity for biopharmaceutical production planned in the U.S., China, Ireland, Germany, and Singapore exceeding 430,000 liters after 2024, WuXi Biologics will provide its biomanufacturing partners with a robust and premier-quality global supply chain network.

오늘 바로 여정을 시작하세요

플랫폼부터 시작해도, 대화부터 시작해도 좋습니다

직접 Pubrio 를 사용하거나, 연구·리드 생성·데이터 통합을 저희 팀에 맡겨 보세요.

팀과 상담하기
Start Journey Image
pubrio

Pubrio는 50개 이상의 로컬 소스에서 비즈니스·인물·의도 데이터를 통합해 하나의 글로벌 그래프로 제공, 시장 전체 가시성을 확보하게 합니다.

© 2026 Pubrio. 모든 권리 보유.